Cargando…

Vitamin D Toxicity–A Clinical Perspective

Confusion, apathy, recurrent vomiting, abdominal pain, polyuria, polydipsia, and dehydration are the most often noted clinical symptoms of vitamin D toxicity (VDT; also called vitamin D intoxication or hypervitaminosis D). VDT and its clinical manifestation, severe hypercalcemia, are related to exce...

Descripción completa

Detalles Bibliográficos
Autores principales: Marcinowska-Suchowierska, Ewa, Kupisz-Urbańska, Małgorzata, Łukaszkiewicz, Jacek, Płudowski, Paweł, Jones, Glenville
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158375/
https://www.ncbi.nlm.nih.gov/pubmed/30294301
http://dx.doi.org/10.3389/fendo.2018.00550
_version_ 1783358417210966016
author Marcinowska-Suchowierska, Ewa
Kupisz-Urbańska, Małgorzata
Łukaszkiewicz, Jacek
Płudowski, Paweł
Jones, Glenville
author_facet Marcinowska-Suchowierska, Ewa
Kupisz-Urbańska, Małgorzata
Łukaszkiewicz, Jacek
Płudowski, Paweł
Jones, Glenville
author_sort Marcinowska-Suchowierska, Ewa
collection PubMed
description Confusion, apathy, recurrent vomiting, abdominal pain, polyuria, polydipsia, and dehydration are the most often noted clinical symptoms of vitamin D toxicity (VDT; also called vitamin D intoxication or hypervitaminosis D). VDT and its clinical manifestation, severe hypercalcemia, are related to excessive long-term intake of vitamin D, malfunctions of the vitamin D metabolic pathway, or the existence of coincident disease that produces the active vitamin D metabolite locally. Although VDT is rare, the health effects can be serious if it is not promptly identified. Many forms of exogenous (iatrogenic) and endogenous VDT exist. Exogenous VDT is usually caused by the inadvertent or improper intake of extremely high doses of pharmacological preparations of vitamin D and is associated with hypercalcemia. Serum 25-hydroxyvitamin D [25(OH)D] concentrations higher than 150 ng/ml (375 nmol/l) are the hallmark of VDT due to vitamin D overdosing. Endogenous VDT may develop from excessive production of an active vitamin D metabolite – 1,25(OH)(2)D in granulomatous disorders and in some lymphomas or from the reduced degradation of that metabolite in idiopathic infantile hypercalcemia. Endogenous VDT may also develop from an excessive production of 25(OH)D and 1,25(OH)(2)D in congenital disorders, such as Williams–Beuren syndrome. Laboratory testing during routine clinical examinations may reveal asymptomatic hypercalcemia caused by the intake of vitamin D even in doses recommended for the general population and considered safe. That phenomenon, called hypersensitivity to vitamin D, reflects dysregulated vitamin D metabolism. Researchers have proposed many processes to explain VDT. Those processes include elevated activity of 1α-hydroxylase or inhibited activity of 24-hydroxylase, both leading to increased concentration of 1,25(OH)D; increased number of vitamin D receptors; and saturation of the capacity of vitamin D binding protein. Increased public awareness of vitamin D–related health benefits might increase the risk of VDT due to self-administration of vitamin D in doses higher then recommended for age and body weight or even higher than the established upper limit intake values. Consequently, the incidence of hypercalcemia due to hypervitaminosis D might increase.
format Online
Article
Text
id pubmed-6158375
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-61583752018-10-05 Vitamin D Toxicity–A Clinical Perspective Marcinowska-Suchowierska, Ewa Kupisz-Urbańska, Małgorzata Łukaszkiewicz, Jacek Płudowski, Paweł Jones, Glenville Front Endocrinol (Lausanne) Endocrinology Confusion, apathy, recurrent vomiting, abdominal pain, polyuria, polydipsia, and dehydration are the most often noted clinical symptoms of vitamin D toxicity (VDT; also called vitamin D intoxication or hypervitaminosis D). VDT and its clinical manifestation, severe hypercalcemia, are related to excessive long-term intake of vitamin D, malfunctions of the vitamin D metabolic pathway, or the existence of coincident disease that produces the active vitamin D metabolite locally. Although VDT is rare, the health effects can be serious if it is not promptly identified. Many forms of exogenous (iatrogenic) and endogenous VDT exist. Exogenous VDT is usually caused by the inadvertent or improper intake of extremely high doses of pharmacological preparations of vitamin D and is associated with hypercalcemia. Serum 25-hydroxyvitamin D [25(OH)D] concentrations higher than 150 ng/ml (375 nmol/l) are the hallmark of VDT due to vitamin D overdosing. Endogenous VDT may develop from excessive production of an active vitamin D metabolite – 1,25(OH)(2)D in granulomatous disorders and in some lymphomas or from the reduced degradation of that metabolite in idiopathic infantile hypercalcemia. Endogenous VDT may also develop from an excessive production of 25(OH)D and 1,25(OH)(2)D in congenital disorders, such as Williams–Beuren syndrome. Laboratory testing during routine clinical examinations may reveal asymptomatic hypercalcemia caused by the intake of vitamin D even in doses recommended for the general population and considered safe. That phenomenon, called hypersensitivity to vitamin D, reflects dysregulated vitamin D metabolism. Researchers have proposed many processes to explain VDT. Those processes include elevated activity of 1α-hydroxylase or inhibited activity of 24-hydroxylase, both leading to increased concentration of 1,25(OH)D; increased number of vitamin D receptors; and saturation of the capacity of vitamin D binding protein. Increased public awareness of vitamin D–related health benefits might increase the risk of VDT due to self-administration of vitamin D in doses higher then recommended for age and body weight or even higher than the established upper limit intake values. Consequently, the incidence of hypercalcemia due to hypervitaminosis D might increase. Frontiers Media S.A. 2018-09-20 /pmc/articles/PMC6158375/ /pubmed/30294301 http://dx.doi.org/10.3389/fendo.2018.00550 Text en Copyright © 2018 Marcinowska-Suchowierska, Kupisz-Urbańska, Łukaszkiewicz, Płudowski and Jones. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Marcinowska-Suchowierska, Ewa
Kupisz-Urbańska, Małgorzata
Łukaszkiewicz, Jacek
Płudowski, Paweł
Jones, Glenville
Vitamin D Toxicity–A Clinical Perspective
title Vitamin D Toxicity–A Clinical Perspective
title_full Vitamin D Toxicity–A Clinical Perspective
title_fullStr Vitamin D Toxicity–A Clinical Perspective
title_full_unstemmed Vitamin D Toxicity–A Clinical Perspective
title_short Vitamin D Toxicity–A Clinical Perspective
title_sort vitamin d toxicity–a clinical perspective
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158375/
https://www.ncbi.nlm.nih.gov/pubmed/30294301
http://dx.doi.org/10.3389/fendo.2018.00550
work_keys_str_mv AT marcinowskasuchowierskaewa vitamindtoxicityaclinicalperspective
AT kupiszurbanskamałgorzata vitamindtoxicityaclinicalperspective
AT łukaszkiewiczjacek vitamindtoxicityaclinicalperspective
AT płudowskipaweł vitamindtoxicityaclinicalperspective
AT jonesglenville vitamindtoxicityaclinicalperspective